Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Deferred Taxes (2019 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Deferred Taxes for 8 consecutive years, with $103.2 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 5491.12% to $103.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.4 million through Dec 2025, up 1356.45% year-over-year, with the annual reading at $81.4 million for FY2025, 1356.45% up from the prior year.
  • Deferred Taxes hit $103.2 million in Q4 2025 for Vanda Pharmaceuticals, up from -$6.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $103.2 million in Q4 2025 to a low of -$8.0 million in Q2 2025.
  • Historically, Deferred Taxes has averaged $4.1 million across 5 years, with a median of $85500.0 in 2022.
  • Biggest YoY gain for Deferred Taxes was 5491.12% in 2025; the steepest drop was 3069.51% in 2025.
  • Year by year, Deferred Taxes stood at $1.3 million in 2021, then tumbled by 68.24% to $417000.0 in 2022, then tumbled by 1894.72% to -$7.5 million in 2023, then surged by 74.43% to -$1.9 million in 2024, then skyrocketed by 5491.12% to $103.2 million in 2025.
  • Business Quant data shows Deferred Taxes for VNDA at $103.2 million in Q4 2025, -$6.0 million in Q3 2025, and -$8.0 million in Q2 2025.